FDA clears MRI-based AI software for predicting Alzheimer’s progression in mild cognitive impairment

FDA clears NEXT-Cue, an AI software that combines brain MRI, cognitive, and demographic data to predict progression from mild cognitive impairment to Alzheimer’s disease within five years.

• Intended to aid prognostic assessment over a five-year horizon.
• Integrates MRI analysis with cognitive and demographic inputs.
• Marks NeuroXT's entry into the U.S. healthcare market.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.